Loading clinical trials...

Study on the microRNA Expression Level in Postmenopausal Osteoporosis | Clinical Trials | Clareo Health

COMPLETED

Study on the microRNA Expression Level in Postmenopausal Osteoporosis

Study on the Molecular Mechanism in Postmenopausal Osteoporosis With Kidney Yin Deficiency Syndrome Based on miRNA Mediated Gene Translation Regulation Function by Targeting CLCF1

NCT02128009•Fujian Academy of Traditional Chinese Medicine

View on ClinicalTrials.gov

Summary

The miRNA plays an important regulation role in gene expression, and also closely related to bone metabolism. Previous research found that postmenopausal osteoporosis with kidney Yin deficiency syndrome (POP) is associated with CLCF1 gene. This project proposed by bioinformatics prediction CLCF1 targeted regulation of miRNAs, and use the 3 'UTR dual luciferase report system for target validation, aimed at the miRNA levels to explore postmenopausal osteoporosis molecular mechanism with kidney Yin deficiency syndrome.

Eligibility

Age

45 - 75 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•The Participants who volunteer to be test subjects, and can accept experimental drugs, and promise to finish the course should sign the informed consent.
•Female ages 45 to 75 had gone through natural menopause before two years
•In accordance with the western medicine diagnostic criteria of osteoporosis and belong to kidney Yin deficiency syndrome differentiation of traditional Chinese medicine certificate;
•In accordance with the western medicine diagnostic criteria;
•In accordance with TCM diagnostic methods; .If any of the above answers are no, The subjects couldn't in the study.

Exclusion Criteria

•Do not accord with standard of the western medicine diagnosis and TCM diagnostic methods
•Age: \<44 and \> 76 years old;
•With hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma and other serious complications such as secondary osteoporosis; Late or deformity, disability, loss of labor;
•With cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases;
•Psychosis or alzheimer's patients;
•Nearly three months, the use of hormone replacement therapy (HRT) and taking calcitonin, nearly six months has used double phosphonic acid salt for 15 days, etc.;
•This medicine allergic constitution or composition of known to have allergies;
•In a critical condition, It's difficult to make exact evaluators to efficacy and safety of the new drugs;

Locations (1)

Fujian Institute of Trational Chiness Medicine

Fuzhou, Fujian, China

Key Dates

Start Date

February 1, 2014

Primary Completion Date

December 1, 2016

Completion Date

January 1, 2017

Last Updated

February 26, 2019

Enrollment

ACTUAL participants

Conditions

Postmenopausal Osteoporosis

Interventions

osteoporosis

OTHER

Anabolic Therapy in Postmenopausal Osteoporosis

NCT05010590

Postmenopausal Osteoporosis

View study

NOT_YET_RECRUITING

AGE Burden and Response to Antiresorptive Therapy in Osteoporosis

NCT07329543

OsteoporosisPostmenopausal Osteoporosis

View study

WITHDRAWNNA

Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 26, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study on the microRNA Expression Level in Postmenopausal Osteoporosis

Inclusion Criteria

Exclusion Criteria

Anabolic Therapy in Postmenopausal Osteoporosis

AGE Burden and Response to Antiresorptive Therapy in Osteoporosis

Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis

A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis